Managed care in the genomics era: Assessing the cost effectiveness of genetic tests

American Journal of Managed Care

Volumn 9, Issue 7, 2003, Pages 493-500

  Higashi, Mitchell K ^a   Veenstra, David L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOCHROME P450 2C9; INTERLEUKIN 1; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; WARFARIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTICOAGULATION; ARTICLE; ASSAY; BIOMEDICAL TECHNOLOGY ASSESSMENT; BLEEDING; BLOOD TOXICITY; BREAST CANCER; COLON CANCER; COLORECTAL CANCER; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; GENETIC ANALYSIS; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HEALTH CARE COST; HUMAN; INCIDENCE; MANAGED CARE; MARKETING; MEDICAL DECISION MAKING; MEDICAL ETHICS; MEDICAL GENETICS; MEDICOLEGAL ASPECT; OUTCOMES RESEARCH; PERIODONTITIS; PHARMACOGENOMICS; PILOT STUDY; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SOCIAL ASPECT; TREATMENT OUTCOME; DECISION MAKING; ECONOMICS; GENETIC PREDISPOSITION; HEALTH INSURANCE; HEALTH SERVICES RESEARCH; HUMAN GENOME PROJECT; INSURANCE; METHODOLOGY; REVIEW; UNITED STATES;

COST-BENEFIT ANALYSIS; DECISION MAKING; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HEALTH SERVICES RESEARCH; HUMAN GENOME PROJECT; HUMANS; INSURANCE CLAIM REVIEW; INSURANCE COVERAGE; MANAGED CARE PROGRAMS; UNITED STATES;

EID: 0041765746     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. JAMA, 2001;286:2270-2279.
2. Sullivan SD, Lyles A, Luce B, Grigar J. AMCP guidance for submission of clinical and economic evaluation data to support formulary listing in U.S. health plans and pharmacy benefits management organizations. J Manag Care Pharm. 2001;7:272-282.
3. Mather DB, Sullivan SD, Augenstein D, Fullerton DS, Athlerly D. Incorporating clinical outcomes and economic consequences into drug formulary decisions: A practical approach. Am J Manag Care. 1999;5:277-285.
4. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ. 1997;16:1-31.
5. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1253-1258.
6. Drummond M, Dubois D, Garattini L, et al. Current trends in the use of pharmacoeconomics and outcomes research in Europe. Value in Health. 1999;2:323-332.
7. Canadian Coordinating Office for Health Technology Assessment. Guidelines for Economic Evaluation of Pharmaceuticals. 2nd ed. Ottawa, Canada: The Canadian Coordinating Office for Health Technology Assessment; 1997. Available at: http://www.ccohta.ca/entry_e.html. Accessed November 1, 2002.
8. Veenstra DL, Higashi MK, Phillips KA. Assessing the cost-effectiveness of pharmacogenomics. AAPS Pharmsci. 2000;2(3):article 29. Available at: http://www.pharmsci.org/scientificjournals/pharmsci/journal/29.html. Accessed November 1, 2002.
9. Holtzman NA, Marteau TM. Will genetics revolutionize medicine? N Engl J Med. 2000;343:141-144.
10. Burke W, Pinsky LE, Press NA. Categorizing genetic tests to identify their ethical, legal, and social implications. Am J Med Genet. Fall 2001;106:233-240.
11. Ponz de Leon M. Descriptive epidemiology of hereditary non-polyposis colorectal cancer. Tumori. 1996;8:102-106.
12. Ramsey SD, Clarke L, Etzioni R, Higashi M, Berry K, Urban N. Cost effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med. 2001;135(8 pt 1):577-588.
13. Kornman KS, Crane A, Wang H-Y, et al. The interleukin-1 genotype as a severity factor in adult periodontal disease. J Clin Periodontol. 1997;24:72-77.
14. Greenstein G, Hart TC. A critical assessment of interleukin-1 (IL-1) genotyping when used in a genetic susceptibility test for severe chronic periodontitis. J Periodontol. 2002;73:231-247.
15. Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA. 1998;279:955-957.
16. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 1996;6:341-349.
17. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2000;287:1690-1698.
18. Krynetski EY, Evans WE. Pharmacogenetics as a molecular basis for individualized drug therapy: The thiopurine S-methyltransferase paradigm. Pharm Res. 1991;16:342-349.
19. Gelehrter TD, Collins FS, Ginsburg D. Principles of Medical Genetics. 2nd ed. Baltimore, Md: Williams & Wilkins; 1998.
20. McGuire MK, Nunn ME. Prognosis versus actual outcome, IV: The effectiveness of clinical parameters and IL-1 genotype in accurately predicting prognoses and tooth survival. J Periodontol. 1999;70:49-56.
21. Syngal S, Fox EA, Li C, et al. Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: Implications for clinical predisposition testing. JAMA. 1999;282:247-253.
22. Nakahara M, Yokozaki H, Yasui W, Dohi K, Tahara E. Identification of concurrent germ-line mutations in hMSH2 and/or hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds. Cancer Epidemiol Biomarkers Prev. 1997;6:1057-1064.
23. Lynch HT, Smyrk TC. Hereditary colorectal cancer. Semin Oncol. 1999;26:478-484.
24. Nasu K, Kubota T, Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics. 1997;7:405-409.
25. Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit. 1998;20:243-247.
26. Dickmann LJ, Rettie AE, Kneller MB, et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol. 2001;60:382-387.
27. Wang SL, Huang J, Lai MD, Tsai JJ. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics. 1995;37-42.
28. Flowers C, Veenstra DL. Will pharmacogenomics in oncology be cost-effective? Oncology Econ. 2000;1:26-33.
29. Leone FT, Mauger EA, Peters SP, et al, for the Asthma Clinical Research Network of the National Heart, Lung, and Blood Institute. The utility of peak flow, symptom scores, and beta-agonist use as outcome measures in asthma clinical research. Chest. 2001;119:1027-1033.
30. Psaty BM, Siscovick DS, Weiss NS, et al. Hypertension and outcomes research. From clinical trials to clinical epidemiology. Am J Hypertens. 1996;9:178-183.
31. Cox A, Camp NJ, Cannings C, et al. Combined sib-TDT and TDT provide evidence for linkage of the interleukin-1 gene cluster to erosive rheumatoid arthritis. Hum Mol Genet. 1999;8:1707-1713.
32. Jouvenne P, Chaudhary A, Buchs N, Giovine FS, Duff GW, Miossec P. Possible genetic association between interleukin-1 alpha gene polymorphism and the severity of chronic polyarthritis. Eur Cytokine Netw. 1999;10:33-36.
33. Kastrani A, Koch W, Berger PB, et al. Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. J Am Coll Cardiol. 2000;36:2168-2173.
34. Nemetz A, Nosti-Escanilla MP, Molnar T, et al. IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease. Immunogenetics. 1999;49:527-531.
35. Collins FS. Genetics: An explosion of knowledge is transforming clinical practice. Geriatrics. 1999;54:41-47.
36. Friend SH. How DNA microarrays and expression profiling will affect clinical practice. BMJ. 1999;319:1-2.
37. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation: A multicenter study. Ann Intern Med. 1993;118:511-520.
38. Vastag B. Experts wrestle with social, ethical implications of human genome research. JAMA. 2001;285:721-722.
39. Coon DW, Davies H, McKibben C, Gallagher-Thompson D. The psychological impact of genetic testing for Alzheimer disease. Genet Test. 1999;3:121-131.
40. Lerman C, Croyle RT. Emotional and behavioral responses to genetic testing for cancer susceptibility. Oncology. 1996;10:191-199.
41. Lerman C, Narod S, Schulman K, et al. BRCA1 testing in families with hereditary breast-ovarian cancer. JAMA. 1996;275:1885-1892.
42. Lerman C, Daly M, Masny A, Balshem A. Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol. 1994;12:843-850.
43. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet. 2000;355(9220):2015-2020.
44. Graham ID, Logan DM, Hughes-Benzie R, et al. How interested is the public in genetic testing for colon cancer susceptibility? Report of a cross-sectional population survey. Cancer Prev Control. 1998;2:167-172.